Rituximab biosimilar (Bioxpress)

利妥昔单抗生物类似药 (Bioxpress)

Report date: 2024/12/30 16:42:42

Base Information

Drug NameRituximab biosimilar (Bioxpress)

Drug Alias NameBXT-2336BX 2336

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsPemphigusMicroscopic PolyangiitisGranulomatosis with Polyangiitis +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

Originator CompaniesBioxpress Therapeutics Sa

China Registration ClassN/A

Develop Information

Active CompaniesBioxpress Therapeutics Sa

Inactive CompaniesN/A

Active IndicationsPemphigusMicroscopic PolyangiitisGranulomatosis with Polyangiitis +[6]

Inactive IndicationsN/A

Other Information

ATC CodeN/A